Holly RUMERY, N/A  - N/A - Owner founder

Holly RUMERY

N/A

N/A

Owner founder

LINCOLN, NE | United States

Main Specialties: Abdominal Radiology, Addiction Psychiatry, Adolescent Medicine, Adult Reconstructive Orthopaedics, Advanced Heart Failure & Transplant Cardiology, Allergy & Immunology, Anesthesiology, Biochemical Genetics, Biology, Biotechnology, Blood Banking - Transfusion Medicine, Cardiothoracic Radiology, Cardiovascular Disease, Chemical Pathology, Chemistry, Child & Adolescent Psychiatry, Child Abuse Pediatrics, Child Neurology, Clinical & Laboratory Immunology, Clinical Cardiac Electrophysiology, Clinical Neurophysiology, Colon & Rectal Surgery, Craniofacial Surgery, Critical Care Medicine, Cytopathology, Dentistry, Dermatology, Dermatopathology, Developmental-Behavioral Pediatrics, Endocrinology Diabetes & Metabolism, Endovascular Surgical Neuroradiology, Epidemiology, Family Medicine, Family Practice, Female Pelvic Medicine & Reconstructive Surgery, Foot & Ankle Orthopaedics, Forensic Pathology, Gastroenterology, Geriatric Medicine

Additional Specialties: Project management

ORCID logohttps://orcid.org/0000-0002-2688-8592

Holly RUMERY, N/A  - N/A - Owner founder

Holly RUMERY

N/A
Introduction

https://www.crunchbase.com/person/holly-rumery

Holly Rumery Presents The Report of the Cancer Moonshot Task Force
October 17, 2016
Executive Summary
In his 2016 State of the Union Address, President Obama called on Vice President Biden to lead a new, national “Cancer Moonshot” to dramatically accelerate efforts to prevent, diagnose, and treat cancer— to achieve a decade’s worth of progress in 5 years. By leveraging decades of scientific understanding from the study and care of cancer, creating and aggregating immensely powerful datasets, and developing unprecedented science and technological capabilities, we as a Nation are positioned to end cancer as we know it.
In pursuit of this mission, President Obama established the Cancer Moonshot Task Force charged with leveraging federal investments, targeted incentives, private sector efforts, patient engagement initiatives, and more, to support cancer research and enable progress in prevention, diagnosis, and treatment. Never before have so many government agencies come together—committing their leadership and uniting their focus—to tackle the challenges along the spectrum of cancer research and care to improve outcomes for patients.
Private sector collaborations and other efforts spurred by the Vice President’s leadership, in addition to his vision for igniting new innovation within the biomedical research enterprise, are outlined in an accompanying executive report. A Blue Ribbon Panel was also formed, which recommended areas of scientific opportunity to complement the Task Force’s activities. These collective efforts are not intended to replace existing cancer programs, initiatives, and policies already underway, but rather are focused on areas in which a coordinated effort can dramatically accelerate the pace of progress in the fight against cancer.
This report presents the Task Force’s Implementation Plans for accelerating progress, including actions launched under the Cancer Moonshot this year, as well as longer-term plans for continuing momentum into the future. In brief, the organizing framework and recommendations are as follows:
Strategic Goal 1 – Catalyze New Scientific Breakthroughs
We are witnessing widespread and unprecedented optimism that we are on the verge of pivotal advances in oncology research. Under Strategic Goal 1, the Task Force is advancing the pace of scientific discovery by:
• Fostering interdisciplinary approaches for elucidating the biological mechanisms underlying cancer onset and treatment;
• Aligning research and care as a seamless and iterative process; and
• Maximizing the collection and research use of longitudinal data and biospecimens.
Strategic Goal 2 – Unleash the Power of Data
Today researchers are working with an unprecedented amount of data, in part due to the explosion of genomic information, increasing use of electronic health records, and large datasets of clinical, environmental, and public health information. Under Strategic Goal 2, the Task Force is maximizing access to and usability of these data to enhance, improve, and inform the journey of every cancer patient by:
• Enabling a seamless data environment for clinical and research data through shared policies and technologies;
• Unlocking scientific advances through open publication and storage platforms and next- generation computer architectures; and
• Developing a scientific workforce capable of using the open and connected data environment.
Strategic Goal 3 – Accelerate Bringing New Therapies to Patients
The process by which lifesaving products are moved into clinics is poised for transformation, especially given the access to new and innovative strategies for moving an idea from “bench to bedside.” Under Strategic Goal 3, the Task Force is accelerating this transformation by:
• Finding efficiencies in the regulatory review and licensing processes;
• Enhancing data sharing across sectors and incentivizing pre-competitive collaborations; and
• Strengthening the oncology clinical research enterprise.
Strategic Goal 4 – Strengthen Prevention and Diagnosis
As we gain an increasing understanding of the causes of cancer, the public can gain cumulative benefits from the broader arsenal of tools for combatting this devastating disease. Under Strategic Goal 4, the Task Force is strengthening the Nation’s efforts around cancer prevention and diagnosis by:
• Advancing health programs, policies, and outreach to help Americans reduce their cancer risk;
• Strengthening our understanding of environmental determinants of cancer; and
• Enhancing the cancer screening continuum.
Strategic Goal 5 – Improve Patient Access and Care
The Affordable Care Act has provided a unique opportunity for opening the door to health coverage to ensure that patients have access to resources and support throughout their cancer journey. Under Strategic Goal 5, the Task Force is building on this foundation and identifying areas with the greatest potential for meaningful impacts for patients by:
• Improving efficiencies of existing programs and expanding current efforts to increase access to health care;
• Translating knowledge into workable policies to improve cancer prevention, detection, and quality of care; and
• Finding new ways of ensuring each and every patient receives quality care during treatment and survivorship.
With these goals in mind, the Task Force launched a series of activities in 2016 and developed plans to serve as a “blueprint” for future Administrations (summarized in the table below). Ultimately, through the creation of new paradigms for generating, sharing, and integrating research and clinical data to enhance patient care, the Cancer Moonshot can accelerate the delivery of effective cancer prevention strategies, diagnostics, and treatments to patients in communities around the world.
? ii ?
CANCER MOONSHOT IMPLEMENTATION PLAN – “AT-A-GLANCE”
Year 1 Accomplishments and Plans Page
Expediting researchers’ access to cancer compounds for research – National Cancer Institute (NCI) Drug Formulary
8
Strategic computing partnership between the Department of Energy (DOE) and NCI to accelerate precision oncology
8
Department of Defense (DoD) launching groundbreaking longitudinal study to revolutionize precision oncology
8
Preclinical research partnership to evaluate the potential of particle beam radiotherapy 8
Creation of an open access resource for sharing cancer data via the Genomic Data Commons 10
Harnessing big data to transform Veteran health through precision medicine 11 Tri-Agency coalition to enhance cancer care – Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) consortium
12
Creation of a new program to accelerate cancer product regulatory review 16 National Institutes of Health (NIH) public-private partnership for accelerating cancer therapies
16
Forging new partnerships to catalyze new drug discovery and development 17
Patents 4 Patients: Establishment of fast-track review for cancer treatment-related patents 17
Crowdsourcing intellectual property data to guide cancer investments 17 Making clinical research trials more accessible to cancer patients 18
Strengthening and clarifying the requirements for public availability of clinical trial information 18
Promoting human papilloma virus (HPV) vaccination as cancer prevention 21 Partnership to avoid carcinogenic risks by reducing radon exposure 21 Improving patient access to medications and information 25 New federal incentives for coordinated cancer care 25 Improving cancer survivorship through art 25
? iii ?
CANCER MOONSHOT IMPLEMENTATION PLAN – “AT-A-GLANCE”
Plans for Year 2 and Beyond Page Strengthen interactions among agencies and engage additional partners in support of multidisciplinary basic cancer research
9
Expand the implementation of mobile devices and wearable technologies for cancer diagnosis and treatment
9
Create a high-quality performance status tracking system for cancer patients during therapy and long-term follow-up
9
Rapidly analyze the molecular profile of thousands of tumors 12 Create a shared resource of linked clinical datasets 13 Improve the clinical data available for research by creating a tool that converts narrative into standardized data
13
Advance secure and scalable platforms for data and metadata management for sharing and analysis
14
Develop predictive computer algorithms to rapidly develop, test, and validate predictive preclinical models
14
Build collaborative relationships with the private sector and academia 14 Create a knowledgeable, sustainable, and agile biomedical data science workforce 15 Modernize eligibility criteria for clinical trials 18 Pilot large simple trials 18 Develop site/tissue agnostic trials and broaden indications 19 Increase the usage of common control and expansion cohort trials 19 Achieve greater interaction with pharmaceutical sponsors on international trials 19 Create a pilot program for oncology products that utilize real-world evidence 20 Strengthen the quality of intellectual property rights to invest in innovation 20 Improve HPV vaccination rates in the United States 22 Implement smoking cessation strategies across the Medicaid population 23 Screen environmental chemicals through high-throughput in vitro assays 23 Expand colorectal cancer screening efforts in the United States 24 Remove barriers that limit access to colorectal cancer screening 24 Identify and implement culturally and linguistically appropriate cancer education and outreach efforts
26
Require expedited coverage decisions for patients with a cancer diagnosis in the Department of Veterans Affairs system
26
Comprehensively identify cancer survivorship issues and develop solutions to improve health outcomes for cancer survivors
26
Map cancer service delivery and care across the Nation 27 Improve access to care by leveraging technology such as virtual networks 27
? iv ?
Cancer Moonshot Task Force
Joseph Biden, Jr
Vice President, United States
Members
Charles Bolden, Jr
Administrator, National Aeronautics and Space Administration
Sylvia Mathews Burwell
Secretary, Department of Health and Human Services
Robert Califf, MD
Commissioner, Food and Drug Administration
Ashton Carter, PhD
Secretary, Department of Defense
Jane Chu, PhD
Chairman, National Endowment for the Arts
Francis Collins, MD, PhD
Director, National Institutes of Health
France Córdova, PhD
Director, National Science Foundation
Shaun Donovan
Director, White House Office of Management and Budget
Thomas Frieden, MD, MPH
Director, Centers for Disease Control and Prevention
Michael Froman, PhD, JD
Ambassador, Trade Representative
John Holdren, PhD
Director, White House Office of Science and Technology Policy
Douglas Lowy, MD
Acting Director National Cancer Institute, National Institutes of Health
Gina McCarthy
Administrator, Environmental Protection Agency
Robert McDonald
Secretary, Department of Veterans Affairs
Ernest Moniz, PhD
Secretary, Department of Energy
Cecilia Muñoz
Director, White House Domestic Policy Council
Penny Pritzker, JD
Secretary, Department of Commerce
Andrew Slavitt
Acting Administrator, Centers for Medicare & Medicaid Services
Thomas Vilsack, JD
Secretary, Department of Agriculture
Jeffrey Zients
Director, White House National Economic Council
? v ?
Cancer Moonshot Task Force Staff
Greg Simon, JD Executive Director
Lyric Jorgenson, PhD Deputy Executive Director
Danielle Carnival, PhD Chief of Staff and Senior Policy Director
Jerry Lee, PhD Deputy Director for Cancer Research and Technologies
Lauren Leiman, MBA Senior Director for External Partnerships
Anabella Aspiras, BSN, MPA Director for Patient Engagement
Kara DeFrias, MEd Director of User Experience
Lynne O’Brien, JD Policy Analyst
Katie Collins Policy Analyst
Kathi Hanna, MS, PhD Science Writer
Leon Fuerth Organizational Analyst
vi ? ?
Table of Contents
Executive Summary ........................................................................................................................................ i
Strategic Goal 1 – Catalyze New Scientific Breakthroughs ........................................................................ i
Strategic Goal 2 – Unleash the Power of Data ........................................................................................... i
Strategic Goal 3 – Accelerate Bringing New Therapies to Patients .......................................................... ii
Strategic Goal 4 – Strengthen Prevention and Diagnosis ......................................................................... ii
Strategic Goal 5 – Improve Patient Access and Care ................................................................................ ii
Cancer Moonshot Task Force ........................................................................................................................ v
Cancer Moonshot Task Force Staff .............................................................................................................. vi
The Opportunity: Ending Cancer as We Know It .......................................................................................... 1
The Launch: Establishment of a Cancer Moonshot Task Force .................................................................... 3
Charting the Course: Organizational Framework ......................................................................................... 5
Liftoff: Cancer Moonshot Implementation Plan ........................................................................................... 6
Strategic Goal 1 – Catalyze New Scientific Breakthroughs ....................................................................... 6
Year 1 Accomplishments and Plans ...................................................................................................... 7
Plans for Year 2 and Beyond ................................................................................................................. 9
Strategic Goal 2 – Unleash the Power of Data ........................................................................................ 10
Year 1 Accomplishments and Plans .................................................................................................... 10
Plans for Year 2 and Beyond ............................................................................................................... 12
Strategic Goal 3 – Accelerate Bringing New Therapies to Patients ........................................................ 16
Year 1 Accomplishments and Plans .................................................................................................... 16
Plans for Year 2 and Beyond ............................................................................................................... 18
Strategic Goal 4 – Strengthen Prevention and Diagnosis ....................................................................... 20
Year 1 Accomplishments and Plans .................................................................................................... 21
Plans for Year 2 and Beyond ............................................................................................................... 22
Strategic Goal 5 – Improve Patient Access and Care .............................................................................. 24
Year 1 Accomplishments and Plans .................................................................................................... 25
Plans for Year 2 and Beyond ............................................................................................................... 26
Reaching Target: Ending Cancer as We Know It ......................................................................................... 29
vii ? ?
The Opportunity: Ending Cancer as We Know It
"For the loved ones we've all lost, for the family we can still save, let's make America
the country that cures cancer once and for all.” - President Barack Obama
Recognizing this unique moment in the fight against cancer, in his 2016 State of the Union Address, President Obama called on Vice President Biden to lead a new, national “Cancer Moonshot” to dramatically accelerate efforts to prevent, diagnose, and treat cancer—to achieve a decade’s worth of progress in 5 years. The progress we have made in understanding cancer in all its forms over the last several decades and the declining death rate from cancer since the early 1990s1 have shown that a future may be possible wherein:
• all segments of society have access to prevention strategies, diagnostics, and treatments that save lives;
• there are cures for some forms of cancer and others have been turned into chronic conditions that do not diminish the quality or length of life;
• cancer researchers and doctors are collaboratively engaged in a system that accelerates knowledge and breakthroughs; and
• patients and health care professionals are partners, and patients can easily access and control their health information to use as they wish, including to further biomedical research.
While bold, the goal of the Cancer Moonshot is within our grasp. Today, society has the benefit of decades of scientific understanding and vast amounts of rich data just waiting to be transformed into solutions. We now know that cancer is hundreds of diseases, largely of our genome, and we have developed new and innovative ways of capitalizing on this knowledge. We know that our behavior and environment contribute to our likelihood of getting cancer, and we are modifying our behaviors and exposures to avoid known risks. We know that prevention and early diagnosis are key to fighting cancer, and we can build these efforts into clinical care.
Added to these advances, today, are immense science and technological capabilities that have positioned us to make a quantum leap in the fight against cancer. For instance, dramatic advances in immunotherapy—engineering our immune system to selectively target cancer cells—has shown remarkable success in treating a host of cancers.2 Over just the last two decades, the cost of whole genome sequencing has fallen from in the range of millions of dollars per genome to below $1,000.3 The increased connectedness of people through smartphones, mobile technologies, electronic health records (EHRs), and the internet allows us to reach people across communities and enables the sharing of essential information key to improving outcomes for patients with cancer. Our ability to store, mine, and analyze the vast array of data from so many sources grows every day,4 and the rise of data science,
1 National Cancer Institute. The Annual Report to the Nation on the Status of Cancer, 1975-2012. 2 Couzin-FJ. Cancer Immunotherapy. Science 20 Dec 2013, 342(6165): 1432-1433. DOI: 10.1126/science.342.6165.1432. 3 National Human Genome Research Institute. The Cost of Sequencing a Human Genome. 4 Ernest Moniz, U.S. Secretary of Energy. Supercomputers Join the Fight Against Cancer. June 15, 2016.
REPORT OF THE CANCER MOONSHOT TASK FORCE
machine learning, and artificial intelligence are rapidly becoming ubiquitous in consumer products.5 And these are just the technologies of today.
Perhaps most importantly, the Cancer Moonshot reflects a shared national commitment to harness the vast intellectual creativity and innovation of the American people to work together to take on the scourge of cancer. The promise of translating research gains into improved treatment options, such as the emergence of precision medicine, coupled with the signing of the Affordable Care Act to expand insurance coverage, the encouraged use of EHRs for patient care, and transitioning to new models of coverage and payment that promote better care at lower cost have provided an important foundation. The Cancer Moonshot aims to realize this promise by leveraging public and private efforts focused on building a system in which patients, researchers, and clinicians can seamlessly share information on treatments and outcomes to accelerate research, guide treatment decisions, and improve cancer outcomes for people across the Nation, and ultimately the world.
The time is now. Together, we can end cancer as we know it.
5 Jason Furman, Chairman Council of Economic Advisors. Is This Time Different? The Opportunities and Challenges of Artificial Intelligence. July 7, 2016.
? 2 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
The Launch: Establishment of a Cancer Moonshot Task Force
President Obama established a first-of-its-kind Cancer Moonshot Task Force (the “Task Force”) uniting 20 federal departments, agencies, and White House Offices under Vice President Biden’s leadership in the fight against cancer. The Task Force was charged with leveraging federal investments, targeted incentives, private sector efforts, patient engagement initiatives, and more, to support cancer research and enable progress in prevention, screening, and treatment. These collective efforts are not intended to replace existing cancer programs, initiatives, and policies already underway, but instead are focused on areas in which a coordinated effort can dramatically accelerate the pace of progress in the fight against cancer.
Concurrent with the launch of the Task Force, President Obama proposed an additional $1 billion investment by the Federal Government to jumpstart the initiative:
• $195 million targeted for cancer activities aligned with the priorities of the Cancer Moonshot at the National Cancer Institute (NCI) in Fiscal Year 2016.
• $755 million in proposed funds for new cancer-related research activities at both the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) in Fiscal Year 2017 (budget request).
• Increased investments by the Department of Defense (DoD) and the Department of Veterans Affairs (VA)—the Nation’s largest public health care providers—by supporting Centers of Excellence focused on specific cancers and by conducting large long-term studies in the military and Veteran populations to define cancer risk factors and improve treatment.
President Obama’s Memorandum also directed the Task Force to consult with external experts, including the presidentially appointed National Cancer Advisory Board (NCAB). To ensure that the mission of the Cancer Moonshot was grounded in the best science, the NCAB formed a Blue Ribbon Panel. Recommendations made by the Blue Ribbon Panel detailing the scientific areas that will benefit from additional funding, support, and coordination were accepted by the NCAB and are described in an accompanying report. The scientific goals outlined in that report are highly synergistic with the areas described throughout this report and are intended to complement the Task Force’s plans.
The Task Force also identified ways in which the Cancer Moonshot could build on the critical accomplishments of this Administration in improving our understanding of cancer and access to cancer care. The President’s aggressive push to increase biomedical research funding generally, and the launch of programs like the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative and the Precision Medicine Initiative (PMI) more specifically, has injected new money and enthusiasm into efforts in genomics, proteomics, technology development, data science, and immunotherapy. Critically, the landmark Affordable Care Act has provided coverage for the uninsured, eliminated discrimination based on pre-existing conditions such as cancer, begun to close the gaps in coverage for seniors needing cancer drugs, and improved access to one of the most effective tools we have against cancer—prevention screenings—without cost sharing.
However, the Cancer Moonshot is a call to action, and its mission cannot be achieved by the Federal Government working alone or in isolation. Thus, in its deliberations, the Task Force sought new ways of
? 3 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
mobilizing partnerships with the private sector and created new opportunities for collaboration. Additional private sector collaborations and efforts spurred by the Vice President’s leadership, in addition to his vision for igniting new innovation within the biomedical research enterprise, are outlined in an accompanying executive report. In sum, the Cancer Moonshot reflects the widespread commitment of the Federal Government, the private sector, scientific researchers, nonprofit organizations, advocates, patients, families, and more working together to catalyze innovation, accelerate progress, and continuously disseminate and act on new knowledge to improve the lives of those facing cancer.
? 4 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
Charting the Course: Organizational Framework
The mission of the Cancer Moonshot—to make a decade’s worth of progress in preventing, diagnosing, and treating cancer in just 5 years—requires renewed efforts across the spectrum of cancer research and care. Thus, the Cancer Moonshot Task Force prioritized early in its discussions the need to have an organizational framework for addressing and uniting these efforts, centered on improving outcomes for patients. In doing so, five strategic goals emerged, which are discussed in further detail in Section IV of this report. Each goal is not only critical to the overall mission, but also is intended to build on
Cancer Moonshot Strategic Goals
and augment the success of the other goals. It is
• Catalyze New Scientific Breakthroughs the coordinated effort across these areas that will
• Unleash the Power of Data ultimately improve the lives of cancer patients and their families.
• Accelerate Bringing New Therapies to Patients Task Force members agreed that this unique
• Strengthen Prevention and Diagnosis opportunity to usher in a new era of cancer
• Improve Patient Access and Care prevention, diagnostics, and therapies can only be achieved if the entire cancer ecosystem works together in new and innovative ways. Efforts pursued under the Cancer Moonshot must complement and build on activities currently underway, but cannot be “business as usual.” The Task Force agreed that to be a “moonshot” any new pursuit must serve a bold purpose and embody a set of core principles that will ensure each effort undertaken has the maximum impact for the community and the individual patient. The following principles are embedded within each strategic goal and throughout the Task Force’s actions and recommendations:
• Drive innovation in the current cancer ecosystem by pursuing audacious, creative, and disruptive approaches;
• Collaborate across disciplines, sectors, and borders to leverage talent and expertise; and
• Share information rapidly to drive advances and crowdsource solutions.
Under the framework established above, the Task Force immediately began working within and across federal departments and agencies to launch a series of focused actions and collaborations to harness resources, programs, personnel, and technology in support of achieving the Cancer Moonshot mission. It established an interagency working group comprising senior leadership across the Federal Government that met bi-weekly to share ideas, discuss challenges, identify new collaborations, and propose new catalytic efforts. Ultimately, the effort engaged staff at multiple levels across the entire Federal Government, demonstrating the deep commitment at all levels to achieve the vision for the Cancer Moonshot as set forth by President Obama and Vice President Biden. Accomplishments spurred by these conversations are described in detail in the next section of this report, along with implementation plans for future activities that can continue to further the Cancer Moonshot’s mission.
? 5 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
Liftoff: Cancer Moonshot Implementation Plan
Many of the Cancer Moonshot activities proposed by the Task Force have already taken shape in 2016. Some were launched at the Cancer Moonshot Summit in June 2016 (see Igniting a National Conversation), while others were launched throughout the year. These efforts are described in further detail in the following sections.
Igniting a National Conversation: Cancer Moonshot Summit
The Cancer Moonshot Summit was convened on June 29, 2016, at Howard University in Washington, D.C. At the event, the Vice President spoke to individuals and organizations representing the entire cancer community and beyond who came together to identify ways to double the rate of progress toward ending cancer as we know it. More than 35 initiatives were announced, reflecting commitments from federal agencies and private sector organizations—industry, nonprofits, foundations, health care systems, and academic institutions—each taking on a piece of the blueprint for the overall Cancer Moonshot mission. In addition, the event inspired more than 300 local summits across all 50 states, Puerto Rico, Guam, and Washington, D.C., engaging more than 7,000 individuals to discuss how they #CanServe by commitment to the goals of the Cancer Moonshot and contributing what they are able.
Plans for continuing momentum under the Cancer Moonshot are provided below as a “blueprint” for future Administrations. These proposals are not intended to be a budget document, as all activities are subject to budgetary constraints and other approvals, including the weighing of priorities and available resources by the Administration in formulating its annual Budget and by Congress in legislating appropriations. However, they are intended to make clear the opportunities on the horizon and the importance of the President’s $1 billion proposal to invest in the Cancer Moonshot.
Strategic Goal 1 – Catalyze New Scientific Breakthroughs
We are witnessing widespread and unprecedented optimism that we are on the verge of pivotal advances in oncology research. This view is based on progress in many areas, including immune-based and targeted therapies, genomics and precision medicine, advanced imaging technologies and other technological innovations, new cell-based and animal preclinical cancer models, greater understanding of the causes and molecular pathogenesis of cancer, and more. As we gain an increasing understanding of basic biology, it becomes readily apparent that greater collaboration across scientific disciplines can propel a more in-depth knowledge of what is possible. Whether it be through understanding the physical properties catalyzing cell movements or the use of nanotechnology to deliver the next critical treatment option, science will be key in driving new options for improving the lives of patients.
Research related to cancer is supported by numerous federal agencies represented on the Cancer Moonshot Task Force and the current understanding of cancer is a direct result of years of public and private investment in basic, translational, and clinical science. But more can be done to catalyze new scientific breakthroughs. Under the Cancer Moonshot, the Federal Government is prioritizing interdisciplinary approaches to elucidate the biological mechanisms underlying cancer onset and
? 6 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
treatment, aligning research and care as a seamless and iterative process, pursuing multidisciplinary initiatives, and maximizing the collection and research use of longitudinal data and biospecimens. Much of this aligns with the Blue Ribbon Panel’s 10 recommended areas of scientific opportunity for NCI investment as part of the Cancer Moonshot (see Blue Ribbon Panel below).
Blue Ribbon Panel Recommendations
Network for direct patient engagement. Engage patients to contribute their comprehensive tumor profile data to expand knowledge about what therapies work, in whom, and in which types of cancer.
Cancer immunotherapy translational science network. Establish a cancer immunotherapy clinical trials network devoted exclusively to discovering and evaluating immunotherapy approaches.
Therapeutic target identification to overcome drug resistance. Identify therapeutic targets to overcome drug resistance through studies that determine the mechanisms that lead cancer cells to become resistant to previously effective treatments.
Creation of a data ecosystem for sharing and analysis. Create a national ecosystem for sharing and analyzing cancer data so that researchers, clinicians, and patients will be able to contribute data, which will facilitate efficient data analysis.
Fusion oncoproteins in pediatric cancer. Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them.
Symptom management research. Accelerate the development of guidelines for routine monitoring and management of patient-reported symptoms to minimize debilitating side effects of cancer and its treatment.
Implementation of evidence-based approaches to prevention. Reduce cancer risk and cancer health disparities through approaches in development, testing, and broad adoption of proven prevention strategies.
Retrospective analysis of biospecimens from patients treated with standard of care. Predict response to standard treatments through retrospective analysis of patient specimens.
Creation of human tumor atlas. Create dynamic 3-D maps of human tumor evolution to document the genetic lesions and cellular interactions of each tumor as it evolves from a precancerous lesion to advanced cancer.
Technology development. Develop new enabling cancer technologies to characterize tumors and test therapies.
Year 1 Accomplishments and Plans
During the first year of the Cancer Moonshot, the Task Force established the foundation for new and more efficient scientific collaborations across federal departments and agencies, leveraging the expertise and reach of each toward a common goal. Efforts launched by the Task Force in Year 1 of the Cancer Moonshot include:
? 7 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
• Expediting Researchers’ Access to Cancer Compounds for Research – NCI’s Drug Formulary
Leveraging lessons learned through the NCI-MATCH (Molecular Analysis for Therapy Choice) clinical trial in which agents developed by different companies are tested alone or in combination under a single study, NCI is forging a public-private partnership with 20 to 30 pharmaceutical and biotechnology companies to expedite cancer researchers’ access to investigational agents and approved drugs. Researchers will be able to obtain compounds through one pre-approved “formulary” list and test them for new purposes or in new combinations, thereby alleviating the need to negotiate with each company independently for individual research projects, which can take as long as 18 months. Ultimately this approach will expedite the start of clinical trials and will bring new options to cancer patients faster. The first agents are expected to be available to the research community by the end of the year.
• Strategic Computing Partnership Between the Department of Energy (DOE) and NCI to Accelerate Precision Oncology
In partnership with NCI, DOE launched three new pilot projects bringing together nearly 100 cancer researchers, care providers, computer scientists, and engineers to apply the Nation's most advanced supercomputing capabilities to analyze data from preclinical models in cancer, molecular interaction data for RAS genes, and cancer surveillance data. Four DOE National Laboratories will conduct the work—Argonne, Los Alamos, Lawrence Livermore, and Oak Ridge— in conjunction with the NCI Frederick National Laboratory for Cancer Research. By joining these forces under a coordinated effort, these projects will refine our understanding of the mechanisms leading to cancer development and thereby accelerate the development of promising therapies that are more effective and less toxic.
• DoD Launching Groundbreaking Longitudinal Study to Revolutionize Precision Oncology
DoD is establishing a groundbreaking new longitudinal study to transform our understanding of the biological underpinnings of cancer. Using the vast amount of data housed within DoD’s cancer registry and serum repository, researchers will work to identify new linkages between pre-diagnostic biological markers and various types of cancer. Approximately 1,000 new cases of cancer occur annually in active duty personnel, and there are approximately 250,000 samples from the last 25 years available to undergo protein signature analysis for pre-incident cancer markers. DoD and the Environmental Protection Agency (EPA) will also work in partnership to link results with the "Environmental Quality Index" to further evaluate the environmental factors contributing to this disease.
• Preclinical Research Partnership to Evaluate the Potential of Particle Beam Radiotherapy
The National Aeronautics and Space Administration (NASA) and NCI are establishing a new collaboration to study the biological effects of particle beam radiotherapy, a novel technology that may deliver a more targeted dose of radiation to tumor cells. Currently, NCI supports several efforts in this area, including comparing the efficacy of carbon ion therapy for the treatment of pancreatic cancer, and NASA is studying the biological effects of a wide range of heavy ions to develop countermeasures for protecting astronauts from the space radiation environment. Under this new partnership, agencies will share data and biospecimens to assess the biological effects of particle beam radiotherapy and evaluate its potential value as a new approach to fighting cancer.
? 8 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
Plans for Year 2 and Beyond
To accomplish the priorities under this Strategic Goal, in addition to the 2016 initiatives described above, several plans for the long term are proposed.
1. Strengthen interactions among agencies and engage additional partners in support of
multidisciplinary basic cancer research.
The complexities of cancer require a multidisciplinary and integrated approach to research. Efforts will be made to inform approaches to molecular modeling by facilitating more formal and robust interactions among mathematicians, modelers, synthetic biologists, and more traditional cancer researchers. These efforts could expand to include DOE, FDA, and NASA. Building on existing agreements, the principal agencies will support a series of workshops to bring multiple disciplines together around key aspects of basic cancer research. An initial workshop was held in October 2016 involving cancer researchers and systems and synthetic biologists to discuss how to engineer the immune system. An IDEAS Lab on topics identified in this first workshop, modeled after the IDEAS Lab on physical and computational approaches to clinical cancer research—jointly funded by a public private partnership involving the National Science Foundation (NSF), NCI, Stand Up to Cancer, and the V Foundation—will be used to catalyze research investments in areas identified in this first workshop. Additional workshops, followed by funding opportunities such as IDEAS Labs, are intended to be developed each year, depending on the availability of funds. The first projects are proposed to be funded in Fiscal Year 2018.
2. Expand the implementation of mobile devices and wearable technologies for cancer diagnosis
and treatment.
Several DoD efforts focused on developing new technologies will be leveraged to fight the war on cancer. First, two projects will center on developing new nanotechnology to increase our ability to visualize and treat cancers at their earliest signs of development. This includes developing imaging systems for real-time analysis to detect microscopic cellular changes, and new laser devices to precisely target surgical interventions in a safer and less invasive manner. Additional projects will develop new technologies and platforms for tracking cellular changes over time, to alert patients and physicians of the earliest stages of cancer onset. These include automated and sensitive systems for tracking changes in moles that indicate future melanomas, and mapping tissue oxygenation to detect and optimize the treatment of cancer throughout the course of therapy. An additional project will develop a "cellular highlighter" to help researchers track the molecular, genomic, and proteomic signatures of cells that appear resistant to cancer treatments. By isolating and analyzing these cells, we can begin to understand the mechanisms underlying treatment-resistant cancers and develop more targeted therapies for affected patients.
3. Create a high-quality performance status tracking system for cancer patients during therapy
and long-term follow-up.
A joint effort between NCI and DoD is aimed at improving the lives of cancer patients undergoing treatment, as well as members of the military attempting to complete a mission. Both cancer patients and military personnel suffer similarly from physical, physiological, and environmental stressors that affect their ability to perform as they each face potentially life- threatening challenges. An accurate, quantitative assessment could prevent doctors from
? 9 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
sending patients for treatment they are not healthy enough to endure—and could help commanding officers avoid sending military personnel on missions they are not healthy enough to complete. The Analytical Tools to Objectively Measure Human Performance (ATOM-HP) project will create a high-quality performance status tracking system for cancer patients during therapy and long-term follow up. The goal is to be able to assess, in real time, a cancer patient’s experiences with physical, psychological, and environmental factors, among others. This is expected to advance the ways by which doctors can monitor core dynamics in cancer patients on a regular basis.
Strategic Goal 2 – Unleash the Power of Data
Data come in all sizes, shapes, and forms, and making sense of this information is essential for developing any new and effective approach to combatting cancer. Today researchers are working with an unprecedented amount of data, in part due to the explosion of genomic information, increasing use of EHRs, and large datasets of clinical, environmental, and public health information. This new era provides a tremendous opportunity for cancer research and care, but also raises significant challenges. Privacy and security issues must be at the forefront of discussions and policy decisions. Making sense of large volumes of data with varying complexity—often referred to as “Big Data”—requires advanced computational capabilities. It is also imperative that data and the insights its analyses generate are rapidly shared as appropriate with researchers, physicians, caregivers, and patients to guide new discoveries and treatment decisions.
Under the Cancer Moonshot, the Task Force is unleashing the power of data to enhance, improve, and inform the journey of every cancer patient from the point of diagnosis through survivorship. To realize this ambitious goal, three priority areas are being tackled: (1) enabling a seamless data environment through shared policies and technologies, (2) unlocking scientific advances through open computational and storage platforms and next generation computer architectures, and (3) developing a workforce capable of using the open and connected data environment. Ultimately, smart collection and use of data can enable the creation of a “learning health care system for cancer,” where as a Nation we learn from the contributed knowledge and experience of every cancer patient.
Year 1 Accomplishments and Plans
The Task Force launched several foundational initiatives in the first year of the Cancer Moonshot to further the vision of establishing a national learning health care system for cancer. Efforts in Year 1 include:
• Creation of an Open Access Resource for Sharing Cancer Data via the Genomic Data Commons
As part of the Cancer Moonshot and the President’s Precision Medicine Initiative (see box), Foundation Medicine is more than doubling the total number of patients represented within the NCI's Genomic Data Commons (GDC), bringing its total to over 32,000 patients accumulated in just over a month. At its launch in early June, the GDC already shared more than five petabytes of raw unprocessed genomic data from large research projects on nearly 30 tumor types from more than 14,000 patients, along with associated clinical data (e.g., clinical diagnosis, treatment history, survival data), creating a foundational system for broad sharing and analysis of cancer genomic data, which is critical for advancing the field of precision medicine and improving the care of cancer patients.
? 10 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
The GDC is complemented by the NCI Genomics Cloud Pilots, which were recently funded for an additional year with the goal of co-locating the computational tools developed by the three Cloud Pilots with the GDC to create a cohesive model for large-scale genomic data management and analysis. The pilots also aim to expand the GDC to other data types, such as proteomics or imaging data. The Cloud Pilots are an important part of exploring new mechanisms for data access, computation, and analysis for cancer data. The Pilots are a partnership of The Broad Institute, The Institute for Systems Biology, and Seven Bridges Genomics. They went public in Spring 2016 and are under active evaluation through September 2017. Most recently, as part of the Cancer Moonshot, NCI jointly announced a new public-private partnership designed to build a sustainable model for maintaining cancer genomic data in the cloud for use by cancer researchers through the GDC and the Genomics Cloud Pilots.
President’s Precision Medicine Initiative
Precision medicine is an emerging approach for disease prevention and treatment that takes into account individual variability in genes, environment, and lifestyle. While we have seen important successes in precision medicine, notably in cancer, the practice is not currently in use for most diseases.
To expedite progress on this front, on January 30, 2015, President Obama launched the Precision Medicine Initiative as a bold new effort focused on catalyzing advances in personalized care. As part of this effort, NIH is supporting a precision oncology component, which focuses on using tumor samples and clinical information from patients to study the development and spread of cancer, elucidating the cellular and molecular changes that give rise to cancer, understanding treatment responses and therapeutic resistance, developing the national information technology infrastructure for future clinical trials, and testing targeted cancer therapies in partnership with patients nationwide through the NCI-MATCH (Molecular Analysis for Therapy CHoice) Trial. Taken together, this national effort mobilizes researchers, providers, and patients to work together in partnership to develop individualized care.
• Harnessing Big Data to Transform Veteran Health through Precision Medicine
VA and DOE formed a new collaboration to apply the most powerful computational assets at DOE’s National Labs to more than half a million Veterans' records from one of the world's largest research cohorts—the Million Veteran Program, a cornerstone of the President’s Precision Medicine Initiative. This is a 5-year, renewable commitment with $3.5 million allocated in Fiscal Year 2016. The first phase of this partnership will focus on cancer, cardiovascular disease, and mental health issues, and the resulting platform will accelerate our understanding of disease detection, progression, prevention, and treatment by combining the rich clinical, environmental, and genomic data—all while enabling top researchers in the world to perform the most cutting-edge science.
? 11 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
• Tri-Agency Coalition to Enhance Cancer Care – Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) Consortium
DoD, VA, and NCI formed a new collaboration using state-of-the-art research methods in proteogenomics to more rapidly identify unique targets and pathways of cancer for detection and intervention—a critical big data challenge. These methods will look at a patient’s genes that may lead to cancer and the expression of these genes in the form of proteins, with potential impact on disease formation and treatment for cancer patients. Initial collaborative efforts will focus on a cohort of 8,000 lung cancer patients within the Nation's two largest health care systems and will make data broadly available to the research community. Ultimately, the effort will be expanded to additional cancer types to reach more cancer patients within VA and DoD, providing knowledge scalable for physicians across the country treating the more than 1.6 million new patients diagnosed with cancer each year.
Plans for Year 2 and Beyond
The Task Force anticipates that the activities described above will continue to grow and expand in scope into Year 2 and beyond, as discussed below. To build on and sustain this momentum, efforts and resources will be needed for developing:
• Best practices for appropriately and respectfully obtaining consent from patients to use their data, and mechanisms for patients to access their health records and contribute them to research such as Sync for Science and Blue Button;
• Effective strategies for generating data standards, especially in cases where there are no existing organizational frameworks;
• Additional mechanisms for making data shareable, especially across multiple repositories and registries, that include approaches to protect data privacy and security;
• New computational and organizational capabilities for obtaining scientific understanding from complex datasets;
• Enhanced strategies for accelerating the translation of basic scientific findings to improved patient outcomes;
• Platforms and collaborations that bring together private-sector data scientists and cancer researchers, such as through data challenges; and
• Incentives for embedding data science training within the research career path and supporting the next generation of data scientists.
Much of the groundwork for these efforts was laid in 2016, with opportunities for sustaining and augmenting them described below.
1. Rapidly analyze the molecular profile of thousands of tumors.
Advances in molecular profiling of patients are difficult to test and rapidly deploy in the current translational pipeline. The APOLLO network (see above) will strengthen and develop research cooperation in using state-of-the-art methods in proteogenomics to characterize and compare tumors, develop a deeper understanding of cancer biology, and identify potential targets and pathways of cancer prevention, detection, and intervention. Developing these methods will lead to better diagnostic tools and effective treatments once disease pathways are discovered.
? 12 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
Collaborations between the APOLLO consortium and the new DoD and VA Infrastructure for Clinical Intelligence (DAVINCI) project will synergize the data-sharing infrastructure. Protocols for data sharing will be reviewed by appropriate Institutional Review Boards and pilot projects will validate the feasibility of sharing existing samples. Ongoing prospective tissue collection will occur into the next 3 years as will mergers with APOLLO genomic and proteomic workflows.
2. Create a shared resource of linked clinical datasets.
Linked clinical datasets, with appropriate and required privacy and security measures, would facilitate better care and potentially and sharing of data for research. Such a resource should link a wide range of datasets, for example, vaccine registries, HIV registries, or administrative data, as well as include a mechanism to identify cancer patient cohorts. Initially, DOD and VA will share data from their respective enterprise data warehouses (medical management and registry capabilities), an effort that has been pioneered in the DAVINCI project. Sharing computable data derived from the two departments’ respective EHRs in a mutually understood data model is one early capability of this effort.
Existing policy and agreements between the departments enable the secure sharing of protected data from the millions of patients who have received care in both systems, which includes nearly all Veterans. Expanding this system will enable a Veteran's health record to be augmented with his or her active duty health record. In the future, the architecture may be expanded to include additional datasets such as radiologic images, and, with appropriate access management and subject consent, data collected in joint research projects. DAVINCI sustainment will be addressed through ongoing modernization and rationalization of the DoD health information technology (IT) portfolio. Resources will be needed to accommodate new use cases as well as currently recognized registry support.
3. Improve the clinical data available for research by creating a tool that converts narrative into
standardized data.
Despite the development and implementation of data standards over the last decade, some health data stored in medical records, laboratory reports, and other clinical reports are only available in free-form text narratives (e.g., clinical notes). Over the next 2 years, the Centers for Disease Control and Prevention (CDC) and FDA will collaborate to create a Natural Language Processing (NLP) Web Service that accepts different types of unstructured health data and returns standardized data for easier integration into databases. When clinical information is incomplete and not available to researchers because it is in narrative rather than data form, research is stymied. This initiative intends to build a resource that can help to solve that problem by converting text into data, which would then be available for quantitative analysis. The NLP Web Service would complement current standardization work. An extensive review of published and existing NLP activities needs to be conducted for possible inclusion on the NLP Web Service, which will be built on a shared platform. Once developed, FDA and CDC intend to pilot test it using cancer data from CDC and surveillance data for blood products and vaccines from FDA. FDA and CDC anticipate that the findings from the pilot project will be used to develop guidance for other federal agencies, public health agencies, academic centers, and commercial vendors as they transition the NLP Web Service into practice. Of note, the NIH-supported Bioportal Annotator API and the NIH Big Data to Knowledge (BD2K) activities include a number of relevant capabilities.
? 13 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
4. Advance secure and scalable platforms for data and metadata management for sharing and
analysis.
Extracting meaningful molecular data from patients with cancer poses significant challenges: data are of different types, they are often stored in disparate repositories, and they contain private information that must be protected. Surmounting these challenges will require collaborative and cooperative efforts to advance secure and scalable platforms for data and metadata management, sharing capabilities for distributed teams of scientists (or virtual organizations), and customized analysis pipelines for high-performance and cloud computing.
The NSF-funded CyVerse project has developed and deployed a cyberinfrastructure platform that currently incorporates state-of-the-art features that could be adapted to meet many of these challenges. CyVerse leadership will host a summit in Winter 2017 to bring together leaders of federal cancer-related projects to discuss common needs and challenges and to explore how capabilities such as those incorporated in the CyVerse platform could meet the challenges. A foreseeable outcome of the summit would be development of ideas for a pilot project to facilitate scalable analysis while preserving privacy of cancer-related datasets used for genotype-to- phenotype analysis via high performance computing workflows. Development of the pilot and submission of a proposal to test it could be completed 60 to 90 days after the workshop. One follow-on activity could carry out the pilot to test enhanced abilities to store, share, and analyze data in a secure environment and to appropriately deliver results to investigators or clinicians while preserving privacy of the underlying data. Next steps could include issuing new solicitations for proposals at the interface of the biological and computational sciences that would leverage and expand capabilities for large-scale analysis of cancer data, with the aim of enabling discovery of the basic underpinnings of cancer development and progression. The results of this research would complement and enhance the predictive capabilities of efforts supported by partner agencies.
5. Develop predictive computer algorithms to rapidly develop, test, and validate predictive
preclinical models.
Combined efforts across NCI and DOE will provide a practical, scalable approach to preclinical screening aimed at opening up new therapeutic options for cancer patients. These models will seek to support the treatment choices of physicians and patients with the goal of achieving the best possible clinical outcome. To lay the groundwork for this effort, a Memorandum of Understanding between DOE and NCI was established in July 2016. It outlines the agencies’ intentions to collaborate in developing a shared technology ecosystem and targeted applications to bring advanced computing capabilities to biological research, thereby transforming drug and treatment development and improving patient care and outcomes. NCI and DOE will begin by: (1) identifying key data gaps, (2) developing initial frameworks and reference implementations, (3) establishing standards of use for data to support model development, and (4) extending involvement to other agencies, academia, and industry. The partnership then aims to develop a set of models that can predict drug responses across a range of cell lines and intends to develop an approach for integrating mechanistic models and mechanism-based constraints into the machine learning framework.
6. Build collaborative relationships with the private sector and academia.
Academic partners not only bring scientific and medical expertise, but they also can provide a richness of data tied to their patient care needs. The technology sector can help co-develop next
? 14 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
generation instruments and technologies at many scales that can be driven by the priority questions being tackled. Drawn together, these can be important resources for unleashing the power of data in cancer treatment. Currently, the University of California, Intel, IBM, and General Electric have engaged DOE and NCI to build on their existing resources, technologies, tools, data, collaborations, and governance expertise to focus on the intersection of technology, cancer, and data. With this collective potential to collect, aggregate, integrate, share and analyze vast and diverse datasets, these partnerships could enable discoveries to transform cancer prevention, detection and diagnosis, accelerate therapeutic development, and advance a patient-centered learning health care system. The overarching vision includes a virtual data ecosystem (drawing from the UCHealth Data Warehouse, which brings together ~15 million patient records), The Parker Institute for Cancer Immunotherapy, Athena Breast Health Network, and the University of California’s five NCI-designated comprehensive cancer centers, and potentially a physical co- location at the University of California, San Francisco, that unites researchers, physicians, engineers and computer scientists from academia, national laboratories, health centers and the private sector. This collaborative, synergistic framework will be a key driver for achieving precision medicine—with cancer at the leading edge. Such a regional center will serve as a powerful model, and hub, for national-scale activity.
7. Create a knowledgeable, sustainable, and agile biomedical data science workforce.
A multi-pronged approach is needed to address the skills and workforce gaps in biomedical data science, from early education exposure to data science of those being trained in the biomedical sciences, to educating established biomedical and clinical investigators about applying computation to biomedical research questions. It is important to note that successful efforts across the Federal Government to achieve these goals are underway and will continue to be a priority. However, to truly support biomedical data science, the Federal Government needs to send a strong signal to the academic community that the development of the tools and algorithms for data analysis is a valued and “legitimate” scientific discipline. This signal should come in the form of dedicated set-aside funding for biomedical data science undergraduate and graduate education by departments and agencies such as DOE, NIH, NSF, and NCI. Support should be included for:
• Undergraduate and graduate education programs
• Cancer data science curriculum development grants (including medical schools)
• Early career grants
• Grants to support integrated teams of biomedical/clinical experts and computational experts, building on efforts such as the NIH/NSF Innovation Lab and the NCI Applied Mathematics in Germinating Oncology Solutions (AMIGOS)
• Interagency fellowship programs to place data science fellows throughout the research and care continuum, building on efforts like VA’s Big Data-Scientist Training Enhancement Program (BD-STEP) to expand to other agencies such as NSF, FDA, or CDC. This should include dedicated resources for VA to manage BD-STEP and build data science curricula and community
• Continuing education workshops in data science for biomedical scientists and physicians
Federal departments and agencies involved in the Cancer Moonshot must also have the capability to recruit top talent and provide training for existing staff for developing, deploying, and disseminating
? 15 ?
REPORT OF THE CANCER MOONSHOT TASK FORCE
novel technologies and best practices for big data analytics. This can be achieved by leveraging and scaling FDA’s Information Exchange and Data Transformation (INFORMED) initiative.
Strategic Goal 3– Accelerate Bringing New Therapies to Patients
The development of lifesaving products for patients depends on the success of moving an idea from “bench to bedside.” The long arc of the commercialization lifecycle—for any product or breakthrough treatment—includes time, capital investments, intellectual property protections, licensing agreements, meaningful clinical trials, robust data analyses, and appropriate regulatory mechanisms that balance patients’ needs with product effectiveness and safety. This process can be arduous for a researcher and frustrating for a patient, often costing too much money and taking too much time.
Under the Cancer Moonshot, a number of federal agencies have convened to find efficiencies in this process, whether it be through enhancing data sharing across sectors, incentivizing pre-competitive collaborations, strengthening the clinical research enterprise, or innovating patent review. For instance, the Task Force prioritized efforts to enhance participation in clinical research while keeping patient safety at the forefront. Through new efficiencies at the U.S. Patent and Trademark Office (USPTO) and new initiatives at FDA, the federal agencies are taking steps to ensure that all efforts are being made to accelerate the delivery of new safe and effective products to patients. DOE and NCI are leveraging high- performance computing applications to gain new insights into patient outcomes. And by releasing such data via third-party application programming interfaces (APIs), academics, application (app) developers, and others can further analyze the efficacy of treatments and develop additional tools for the public, while NIH and others bring new partnerships online to stimulate even more research.
Year 1 Accomplishments and Plans
In Year 1 of the Cancer Moonshot, the Task Force focused on accelerating the pace at which ideas get protected, manufactured, tested, and ushered to clinical treatment centers. Several of these efforts described below will require additional effort spanning the next few years, but the Task Force agreed that their initiation was critical in Year 1 to ensure the swift movement of discoveries to clinical care.
• Creation of a New Program to Accelerate Cancer Product Regulatory Review
FDA hired an Acting Director of its new Oncology Center of Excellence (OCE). The OCE will unite cancer product regulatory review to enhance coordination and leverage the combined skills and clinical expertise across FDA centers. Under the Cancer Moonshot, the Acting Director is charged with accelerating the establishment of a program that brings together oncologists across the FDA in an effort to expedite the development of novel c

Primary Affiliation: N/A - LINCOLN, NE , United States

Specialties:

Additional Specialties:

Research Interests:


View Holly RUMERY’s Resume / CV
Metrics

100

Publications

128

Profile Views

857

Reads

2509

PubMed Central Citations

Education
Sep 2018
Berkley University
Extraterrestrial study
Sep 2005
Tyler junior college
ROTC
Experience
Dec 2011
NASA Ames Research Center
Host /Project Leader / humanitarians activist
Dec 2011
University of California Berkeley
Extraterestrial studys BioMedical agricuture engieering
InnOvOtion by Holly
Bioengineering
Top co-authors
Dara L Aisner
Dara L Aisner

University of Colorado Cancer Center

26
Robert C Doebele
Robert C Doebele

University of Colorado

25
Wilbur A Franklin
Wilbur A Franklin

University of Colorado

14
Fred R Hirsch
Fred R Hirsch

University of Colorado Cancer Center

14
Anh T Le
Anh T Le

School of Economics and Finance

12
Paul A Bunn
Paul A Bunn

University of Colorado Cancer Center

9
Antonio Jimeno
Antonio Jimeno

University of Colorado Cancer Center

9
Wells A Messersmith
Wells A Messersmith

University of Colorado Cancer Center

8
Xian Lu
Xian Lu

University of Colorado Denver

7

Publications

100Publications

857Reads

2509PubMed Central Citations

Resistance Mechanisms to Targeted Therapies in and Non-small Cell Lung Cancer.

Clin Cancer Res 2018 Jul 10;24(14):3334-3347. Epub 2018 Apr 10.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.

View Article
July 2018
11 Reads
8.72 Impact Factor

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.

J Thorac Oncol 2018 Jun 20. Epub 2018 Jun 20.

Department of Medicine - Division of Medical Oncology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado. Electronic address:

View Article
June 2018
6 Reads
5.28 Impact Factor

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.

J Thorac Oncol 2018 Feb 20;13(2):228-236. Epub 2017 Nov 20.

Division of Medical Oncology, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado. Electronic address:

View Article
February 2018
7 Reads
1 PubMed Central Citation(source)
5.28 Impact Factor

Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries.

Am Soc Clin Oncol Educ Book 2017 ;37:403-408

From the University of Colorado School of Medicine, University of Colorado Cancer Center, International Association for the Study of Lung Cancer, Aurora, CO; Institute for Pulmonary Diseases of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; National Cancer Institute, Cairo University, Giza, Egypt; Chiang Mai University, Chiang Mai, Thailand; Pathology Department, Chiang Mai University, Chiang Mai, Thailand; Hospital Italiano Buenos Aires, Perón, Argentina; University of Colorado Anschutz Medical Campus, Aurora, CO.

View Article
December 2017
6 Reads

MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

Clin Cancer Res 2017 Nov 29;23(22):7084-7096. Epub 2017 Aug 29.

Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida.

View Article
November 2017
9 Reads
1 PubMed Central Citation(source)
8.72 Impact Factor

Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.

J Thorac Oncol 2017 Oct 19;12(10):1512-1523. Epub 2017 Jun 19.

Department of Medicine, Division of Medical Oncology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

View Article
October 2017
12 Reads
1 PubMed Central Citation(source)
5.28 Impact Factor

Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.

J Mol Diagn 2017 Sep 9;19(5):682-696. Epub 2017 Aug 9.

Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio; Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, Ohio. Electronic address:

View Article
September 2017
6 Reads
1 PubMed Central Citation(source)
4.85 Impact Factor

A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Oncotarget 2017 Aug 10;8(31):50489-50499. Epub 2016 Jun 10.

Hamon Center for Therapeutic Oncology Research, Department of Pathology and Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.

View Article
August 2017
10 Reads
2 PubMed Central Citations(source)
6.36 Impact Factor

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.

Mol Cancer Ther 2017 08 12;16(8):1623-1633. Epub 2017 May 12.

Division of Medical Oncology, or

View Article
August 2017
16 Reads
1 PubMed Central Citation(source)
5.68 Impact Factor

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 Jul 6;12(7):e85-e88. Epub 2017 Mar 6.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. Electronic address:

View Article
July 2017
1 PubMed Central Citation(source)
5.28 Impact Factor

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Cancer Res 2017 07 20;77(13):3551-3563. Epub 2017 Apr 20.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.

View Article
July 2017
76 Reads
12 PubMed Central Citations(source)
9.33 Impact Factor

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.

PLoS One 2016 26;11(10):e0165107. Epub 2016 Oct 26.

Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA, 30322, United States of America.

View Article
June 2017
4 Reads
3 PubMed Central Citations(source)
3.23 Impact Factor

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

J Thorac Oncol 2017 01 21;12(1):141-144. Epub 2016 Sep 21.

Clinical Oncology, Cancer Institute of the State of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil.

View Article
January 2017
3 Reads
4 PubMed Central Citations(source)
5.28 Impact Factor

An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.

J Thorac Oncol 2016 12 6;11(12):2248-2252. Epub 2016 Sep 6.

University Health Network, Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article
December 2016
6 Reads
1 PubMed Central Citation(source)
5.28 Impact Factor

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

J Thorac Oncol 2016 08 9;11(8):1273-1281. Epub 2016 Apr 9.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, University of Colorado, Aurora, Colorado. Electronic address:

View Article
August 2016
44 Reads
12 PubMed Central Citations(source)
5.28 Impact Factor

Molecular Profiling of a Rare Rosette-Forming Glioneuronal Tumor Arising in the Spinal Cord.

PLoS One 2015 15;10(9):e0137690. Epub 2015 Sep 15.

Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal; 3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.

View Article
May 2016
9 Reads
3 PubMed Central Citations(source)
3.23 Impact Factor

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

J Cancer 2016 20;7(6):633-49. Epub 2016 Mar 20.

3. Department of Medicine, University of Colorado, Anschutz Medical Campus, 12801 East 17th Ave, RC1 South, L18-8118, Mail Stop 8117, Aurora, Colorado, USA 80045.

View Article
April 2016
3 Reads
4 PubMed Central Citations(source)
2.64 Impact Factor

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.

J Thorac Oncol 2016 Mar 24;11(3):414-9. Epub 2015 Dec 24.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.

View Article
March 2016
4 Reads
15 PubMed Central Citations(source)
5.28 Impact Factor

De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissue.

FASEB J 2016 Mar 18;30(3):1096-108. Epub 2015 Nov 18.

*Division of Geriatric Medicine, Division of Medical Oncology, and Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, School of Medicine, Flow Cytometry Shared Resource, Molecular Pathology/Cytogenetics Shared Resource, University of Colorado Cancer Center, Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, and Colorado Obesity Research Initiative, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; Molecular Diagnostic Laboratory, Children's Hospital Colorado, Aurora, Colorado, USA; and Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, and **Center for Stem Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

View Article
March 2016
10 Reads
15 PubMed Central Citations(source)
5.04 Impact Factor

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.

J Thorac Oncol 2015 Dec;10(12):e115-8

Division of Medical Oncology, University of Colorado, Aurora, Colorado.

View Article
December 2015
1 PubMed Central Citation(source)
5.28 Impact Factor

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

J Thorac Oncol 2015 Jul;10(7):1083-90

*Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Institute, Shanghai, People's Republic of China; †Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; ‡Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; §Institute of Pathology, University Hospital Cologne, Medical Centre, Cologne, Germany; ‖Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado; ¶Department of Craniofacial Biology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; and #Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Institute, Shanghai, People's Republic of China.

View Article
July 2015
11 Reads
7 PubMed Central Citations(source)
5.28 Impact Factor

KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.

J Neuropathol Exp Neurol 2015 Jul;74(7):743-54

From the Molecular Oncology Research Center (APB, ACC, AP, RMR), and Department of Pathology (CSN), Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Cancer Center (JS, DLA), and School of Medicine (EM, MVG), University of Colorado, Aurora, Colorado; Department of Neurosurgery(CC), Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Department of Surgery (RSO), and Department of Pathology and Forensic Medicine (APB, LN), Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP), São Paulo, Brazil; Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho (RMR), Braga, Portugal; and ICVS/3B's - PT Government Associate Laboratory(RMR), Braga/Guimarães, Portugal.

View Article
July 2015
6 Reads
12 PubMed Central Citations(source)
3.80 Impact Factor

Macrothrombocytopenia as diagnosis predictor of 22q11 deletion syndrome among patients with congenital heart defects.

Am J Med Genet A 2015 Jun 21;167(6):1406-8. Epub 2015 Apr 21.

Graduate Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.

View Article
June 2015
4 Reads
1 PubMed Central Citation(source)
2.16 Impact Factor

MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Am J Clin Oncol 2015 Apr;38(2):152-8

*Department of Medical Oncology, S. Maria della Misericordia Hospital Departments of †Electronic and Information Engineering ‡Thoracic Surgery §Institute of Pathological Anatomy and Histology, University of Perugia, Perugia, Italy ∥Department of Medicine/Medical Oncology, University of Colorado Cancer Center, Aurora, CO.

View Article
April 2015
5 Reads
3 PubMed Central Citations(source)
2.61 Impact Factor

Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.

Ther Adv Med Oncol 2015 Mar;7(2):56-62

Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365 Clifton Road, NE, Room C3080, Atlanta, GA 30322, USA.

View Article
March 2015
7 Reads
1 PubMed Central Citation(source)

Congenital heart disease in Southern Brazil: potential impact and prevention.

Int J Cardiol 2015 Jan 1;179:9-10. Epub 2014 Nov 1.

Graduate Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), RS, Brazil; Clinical Genetics, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA) and Complexo Hospitalar Santa Casa de Porto Alegre (CHSCPA), RS, Brazil. Electronic address:

View Article
January 2015
4 Reads
4.04 Impact Factor

Role of hypocalcemia in identification of 22q11 deletion syndrome among patients with congenital heart defects.

Int J Cardiol 2014 Nov 5;177(1):6-7. Epub 2014 Oct 5.

Clinical Genetics, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA) and Complexo Hospitalar Santa Casa de Porto Alegre (CHSCPA), RS, Brazil; Graduate Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), RS, Brazil; Clinical Genetics, Hospital Materno Infantil Presidente Vargas (HMIPV), RS, Brazil. Electronic address:

View Article
November 2014
10 Reads
4.04 Impact Factor

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Nov 27;371(21):1963-71. Epub 2014 Sep 27.

From the Massachusetts General Hospital Cancer Center (A.T.S., L.P.L., Z.Z., J.W.C., A.J.I.), Dana-Farber Cancer Institute (G.I.S.), and Beth Israel Deaconess Medical Center (D.B.C.) - all in Boston; University of California at Irvine, Irvine (S.-H.I.O.), and Pfizer Oncology, La Jolla (W.T., S.M.S., L.M.T., J.G.C., K.D.W.) - both in California; Seoul National University Hospital, Seoul, South Korea (Y.-J.B.); University of Colorado, Aurora (D.R.C., M.V.-G., R.C.D.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); University of Chicago, Chicago (R.S.); Memorial Sloan Kettering Cancer Center, New York (G.J.R.); Karolinska Institutet, Stockholm (Z.Z.); and Rho, Chapel Hill, NC (P.S.).

View Article
November 2014
14 Reads
259 PubMed Central Citations(source)
55.87 Impact Factor

Screening for 22q11 deletion syndrome among patients with congenital heart defects.

Sao Paulo Med J 2014 ;132(2):125-6

Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.

View Article
October 2014
2 Reads
0.70 Impact Factor

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

PLoS One 2013 13;8(12):e82236. Epub 2013 Dec 13.

Department of Medicine, Division of Medical Oncology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States of America.

View Article
October 2014
5 Reads
28 PubMed Central Citations(source)
3.23 Impact Factor

Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.

J Thorac Oncol 2014 Mar;9(3):e21-3

*Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Institute, People's Republic of China; †Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado; and ‡Department of Pathology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado.

View Article
March 2014
1 Read
13 PubMed Central Citations(source)
5.28 Impact Factor

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.

Clin Cancer Res 2014 Mar 3;20(6):1656-65. Epub 2014 Feb 3.

Authors' Affiliations: Department of Medicine, Division of Medical Oncology; Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado; and Onconova Therapeutics Inc, Newtown, Pennsylvania.

View Article
March 2014
9 Reads
12 PubMed Central Citations(source)
8.72 Impact Factor

Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions.

Cancer Prev Res (Phila) 2014 Feb 17;7(2):255-65. Epub 2013 Dec 17.

University of Colorado, Anschutz Medical Campus, 12700, East 19th Avenue, RC2 9th Floor, Aurora, CO 80045.

View Article
February 2014
4 Reads
8 PubMed Central Citations(source)

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

Mol Cancer Res 2014 Jan 2;12(1):111-8. Epub 2013 Dec 2.

University of Colorado School of Medicine Anschutz Medical Campus, 12801 East 17th Avenue, L18-8118, Mail Stop 8117, Aurora, CO 80045.

View Article
January 2014
14 Reads
38 PubMed Central Citations(source)
4.38 Impact Factor

Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.

Cancer 2013 Nov 10;119(22):3968-75. Epub 2013 Sep 10.

Department of Medicine, Division of Medical Oncology, University of Colorado, Denver, Colorado.

View Article
November 2013
1 Read
9 PubMed Central Citations(source)
4.89 Impact Factor

Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

Cytotherapy 2013 Nov 28;15(11):1323-39. Epub 2013 Aug 28.

Terumo BCT, Inc, Lakewood, Colorado, USA. Electronic address:

View Article
November 2013
10 PubMed Central Citations(source)
3.29 Impact Factor

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Mol Cancer Ther 2013 Oct 19;12(10):1994-2005. Epub 2013 Jul 19.

Corresponding Author: Antonio Jimeno, University of Colorado School of Medicine, MS8117, 12801 East 17th Avenue, Room L18-8101B, Aurora, CO 80045.

View Article
October 2013
10 Reads
8 PubMed Central Citations(source)
5.68 Impact Factor

Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.

Cancer 2013 Apr 20;119(8):1467-77. Epub 2012 Dec 20.

Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA.

View Article
April 2013
2 Reads
20 PubMed Central Citations(source)
4.89 Impact Factor

[22q11.2 deletion syndrome and complex congenital heart defects].

Rev Assoc Med Bras (1992) 2011 Jan-Feb;57(1):62-5

Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS.

View Article
March 2013
1 Read
2 PubMed Central Citations(source)
0.92 Impact Factor

Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.

Clin Cancer Res 2013 Jan 21;19(1):148-57. Epub 2012 Nov 21.

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

View Article
January 2013
7 Reads
10 PubMed Central Citations(source)
8.72 Impact Factor

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

Clin Cancer Res 2013 Jan 7;19(1):291-303. Epub 2012 Nov 7.

Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO 80045, USA.

View Article
January 2013
4 Reads
16 PubMed Central Citations(source)
8.72 Impact Factor

Malformations detected by abdominal ultrasound in children with congenital heart disease.

Arq Bras Cardiol 2012 Dec 30;99(6):1092-9. Epub 2012 Nov 30.

Programa de Pós-graduação em Patologia, Fundação Universidade Federal de Ciências da Saúde de Porto Alegre, RS, Brasil.

View Article
December 2012
1 Read
1 PubMed Central Citation(source)
1.12 Impact Factor

Oncogenic fusions involving exon 19 of ALK.

J Thorac Oncol 2012 Dec;7(12):e44

Department of Medicine, Division of Medical Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. Electronic address:

View Article
December 2012
5.28 Impact Factor

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.

Cancer 2012 Sep 26;118(18):4502-11. Epub 2012 Jan 26.

Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

View Article
September 2012
9 Reads
1 PubMed Central Citation(source)
4.89 Impact Factor

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Clin Cancer Res 2012 Sep 23;18(17):4570-9. Epub 2012 Aug 23.

Division of Medical Oncology, University of Colorado, MS 8117, 12801 E. 17th Ave, Aurora, CO 80045, USA.

View Article
September 2012
3 Reads
82 PubMed Central Citations(source)
8.72 Impact Factor

Biologic and genetics aspects of chagas disease at endemic areas.

J Trop Med 2012 8;2012:357948. Epub 2012 Mar 8.

Department of Especial Education, UNESP São Paulo State University, 17525-900 Campus Marília, SP, Brazil.

View Article
August 2012
7 Reads
3 PubMed Central Citations(source)

ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.

Mol Oncol 2012 Jun 28;6(3):370-81. Epub 2012 Mar 28.

Division of Medical Oncology, University of Colorado Denver and University of Colorado Cancer Center, Aurora, CO 80045, USA.

View Article
June 2012
4 Reads
16 PubMed Central Citations(source)
5.33 Impact Factor

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

J Clin Oncol 2012 Jun 16;30(18):2248-55. Epub 2012 Apr 16.

University of Colorado Cancer Center, 12801 E 17th Ave, Mail Stop 8117, Aurora, CO 80045, USA.

View Article
June 2012
6 Reads
1 PubMed Central Citation(source)
18.43 Impact Factor

Prognostic patterns in the histopathology of pulmonary adenocarcinoma.

J Clin Oncol 2012 May 5;30(13):1401-3. Epub 2012 Mar 5.

View Article
May 2012
4 Reads
1 PubMed Central Citation(source)
18.43 Impact Factor

Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.

Clin Cancer Res 2012 May;18(9):2704-14

Division of Medical Oncology, University of Colorado Denver and University of Colorado Cancer Center, Denver, Colorado 80045, USA.

View Article
May 2012
7 Reads
15 PubMed Central Citations(source)
8.72 Impact Factor

p95HER2 truncated form in resected non-small cell lung cancer.

J Thorac Oncol 2012 Mar;7(3):520-7

Department of Oncology, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy.

View Article
March 2012
2 Reads
4 PubMed Central Citations(source)
5.28 Impact Factor

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Clin Cancer Res 2012 Mar 10;18(5):1472-82. Epub 2012 Jan 10.

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80209, USA.

View Article
March 2012
13 Reads
270 PubMed Central Citations(source)
8.72 Impact Factor

HIV-1 Tat increases oxidant burden in the lungs of transgenic mice.

Free Radic Biol Med 2011 Nov 5;51(9):1697-707. Epub 2011 Aug 5.

Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

View Article
November 2011
10 PubMed Central Citations(source)
5.74 Impact Factor

Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.

Urology 2011 Oct 2;78(4):863-7. Epub 2011 Aug 2.

Department of Medicine, University of Colorado, School of Medicine, Aurora, CO, USA.

View Article
October 2011
1 Read
1 PubMed Central Citation(source)
2.19 Impact Factor

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.

J Thorac Oncol 2011 Apr;6(4):774-80

Department of Medical Oncology, University of Colorado Denver, 1665 North Ursula Street, Room 2256, P.O. Box 6510, Mail Stop F-706, Aurora, CO 80045-0508, USA.

View Article
April 2011
6 Reads
1 PubMed Central Citation(source)
5.28 Impact Factor

Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.

Clin Cancer Res 2011 Apr 21;17(8):2434-43. Epub 2011 Jan 21.

Departmentsof Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article
April 2011
5 Reads
32 PubMed Central Citations(source)
8.72 Impact Factor

Finding ALK-positive lung cancer: what are we really looking for?

J Thorac Oncol 2011 Mar;6(3):411-3

View Article
March 2011
7 PubMed Central Citations(source)
5.28 Impact Factor

Suppression of leukemia development caused by PTEN loss.

Proc Natl Acad Sci U S A 2011 Jan 6;108(4):1409-14. Epub 2011 Jan 6.

Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA.

View Article
January 2011
1 Read
22 PubMed Central Citations(source)
9.81 Impact Factor

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Clin Cancer Res 2010 Nov 9;16(22):5581-90. Epub 2010 Nov 9.

Division of Medical Oncology and Department of Pathology, University of Colorado-Denver, 1665 North Ursula Street, Aurora, CO 80045-0508, USA.

View Article
November 2010
1 Read
82 PubMed Central Citations(source)
8.72 Impact Factor

[Oculo-auriculo-vertebral spectrum in patients with congenital heart defects].

Arq Bras Cardiol 2010 Oct 3;95(4):436-9. Epub 2010 Sep 3.

Universidade Federal de Ciências da Saúde de Porto Alegre.

View Article
October 2010
2 Reads
1 PubMed Central Citation(source)
1.12 Impact Factor

De novo generation of white adipocytes from the myeloid lineage via mesenchymal intermediates is age, adipose depot, and gender specific.

Proc Natl Acad Sci U S A 2010 Aug 2;107(33):14781-6. Epub 2010 Aug 2.

Charles C Gates Regenerative Medicine and Stem Cell Biology Program, Department of Pediatrics, Cardiovascular Pulmonary Research Laboratory, University of Colorado, Aurora, CO 80045, USA.

View Article
August 2010
9 Reads
51 PubMed Central Citations(source)
9.81 Impact Factor

Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.

Clin Cancer Res 2010 Aug 3;16(16):4165-77. Epub 2010 Aug 3.

Division of Medical Oncology, University of Colorado, Denver, Colorado, USA.

View Article
August 2010
1 Read
12 PubMed Central Citations(source)
8.72 Impact Factor
Top co-authors
Dara L Aisner
Dara L Aisner

University of Colorado Cancer Center

26
Robert C Doebele
Robert C Doebele

University of Colorado

25
Wilbur A Franklin
Wilbur A Franklin

University of Colorado

14
Fred R Hirsch
Fred R Hirsch

University of Colorado Cancer Center

14
Anh T Le
Anh T Le

School of Economics and Finance

12
Paul A Bunn
Paul A Bunn

University of Colorado Cancer Center

9
Antonio Jimeno
Antonio Jimeno

University of Colorado Cancer Center

9
Wells A Messersmith
Wells A Messersmith

University of Colorado Cancer Center

8
Xian Lu
Xian Lu

University of Colorado Denver

7